Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2...
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
- First Posted Date
- 2005-05-26
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 49
- Registration Number
- NCT00111787
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
- First Posted Date
- 2005-03-21
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 126
- Registration Number
- NCT00105950
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 138
- Registration Number
- NCT00089999
- Locations
- 🇨🇳
GSK Investigational Site, Taipei, Taiwan
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
- First Posted Date
- 2003-11-26
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1286
- Registration Number
- NCT00073528
- Locations
- 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
- Conditions
- First Posted Date
- 2002-08-28
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT00044343
- Locations
- 🇨🇦
GSK Clinical Trials Call Center, Sainte-Foy, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.